FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 158 filers reported holding FATE THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is 0.41 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $403 | -83.1% | 122,888 | -62.1% | 0.00% | -100.0% |
Q1 2024 | $2,380 | +77.1% | 324,243 | -9.8% | 0.00% | – |
Q4 2023 | $1,344 | +433.3% | 359,375 | +202.6% | 0.00% | – |
Q3 2023 | $252 | -89.0% | 118,751 | -75.2% | 0.00% | -100.0% |
Q2 2023 | $2,281 | -20.1% | 479,099 | -4.3% | 0.00% | 0.0% |
Q1 2023 | $2,855 | +7.3% | 500,822 | +89.8% | 0.00% | 0.0% |
Q4 2022 | $2,662 | -99.9% | 263,875 | +47.5% | 0.00% | -75.0% |
Q3 2022 | $4,011,000 | +677.3% | 178,915 | +759.5% | 0.00% | – |
Q2 2022 | $516,000 | -37.8% | 20,817 | -2.7% | 0.00% | -100.0% |
Q1 2022 | $830,000 | -93.3% | 21,398 | -89.9% | 0.00% | -50.0% |
Q4 2021 | $12,430,000 | +283.2% | 212,436 | +288.0% | 0.00% | +100.0% |
Q3 2021 | $3,244,000 | -12.2% | 54,748 | +28.7% | 0.00% | -50.0% |
Q2 2021 | $3,693,000 | -59.2% | 42,544 | -61.2% | 0.00% | -60.0% |
Q1 2021 | $9,051,000 | -23.3% | 109,779 | -15.5% | 0.01% | -16.7% |
Q4 2020 | $11,807,000 | +85.8% | 129,849 | -18.3% | 0.01% | +50.0% |
Q3 2020 | $6,355,000 | +35.6% | 158,991 | +16.3% | 0.00% | 0.0% |
Q2 2020 | $4,687,000 | +92.6% | 136,654 | +24.7% | 0.00% | +100.0% |
Q1 2020 | $2,434,000 | +105.1% | 109,572 | +80.7% | 0.00% | +100.0% |
Q4 2019 | $1,187,000 | +38.3% | 60,653 | +9.9% | 0.00% | 0.0% |
Q3 2019 | $858,000 | -44.8% | 55,185 | -27.9% | 0.00% | 0.0% |
Q2 2019 | $1,554,000 | +169.8% | 76,512 | +133.2% | 0.00% | – |
Q1 2019 | $576,000 | +38.5% | 32,806 | +1.1% | 0.00% | – |
Q4 2018 | $416,000 | -23.9% | 32,459 | -3.2% | 0.00% | – |
Q3 2018 | $547,000 | +543.5% | 33,527 | +350.5% | 0.00% | – |
Q2 2018 | $85,000 | -53.8% | 7,442 | -60.4% | 0.00% | – |
Q1 2018 | $184,000 | +384.2% | 18,805 | +201.9% | 0.00% | – |
Q4 2017 | $38,000 | +245.5% | 6,228 | +132.1% | 0.00% | – |
Q3 2017 | $11,000 | -71.1% | 2,683 | -77.0% | 0.00% | – |
Q2 2017 | $38,000 | -67.0% | 11,668 | -53.6% | 0.00% | – |
Q1 2017 | $115,000 | – | 25,143 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JOHNSON & JOHNSON | 3,379,064 | $197,709,000 | 22.51% |
Redmile Group, LLC | 12,957,222 | $758,127,000 | 17.24% |
Grosvenor Holdings, L.L.C. | 1,037,256 | $60,690,000 | 6.28% |
Casdin Capital, LLC | 3,400,000 | $198,934,000 | 5.61% |
Ally Bridge Group (NY) LLC | 270,000 | $15,798,000 | 5.52% |
DAFNA Capital Management LLC | 372,160 | $21,775,000 | 5.48% |
Tri Locum Partners LP | 142,032 | $8,310,000 | 3.27% |
Kynam Capital Management, LP | 95,561 | $5,591,000 | 2.99% |
Artal Group S.A. | 1,800,000 | $105,318,000 | 2.86% |
Bellevue Group AG | 3,775,736 | $220,918,000 | 2.28% |